Your browser doesn't support javascript.
loading
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
Bashir, Qaiser; Thall, Peter F; Milton, Denái R; Fox, Patricia S; Kawedia, Jitesh D; Kebriaei, Partow; Shah, Nina; Patel, Krina; Andersson, Borje S; Nieto, Yago L; Valdez, Ben C; Parmar, Simrit; Rondon, Gabriela; Delgado, Ruby; Hosing, Chitra; Popat, Uday R; Oran, Betul; Ciurea, Stefan O; Lin, Pei; Weber, Donna M; Thomas, Sheeba K; Lee, Hans C; Manasanch, Elisabet E; Orlowski, Robert Z; Williams, Loretta A; Champlin, Richard E; Qazilbash, Muzaffar H.
Afiliación
  • Bashir Q; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA. Electronic address: qbashir@mdanderson.org.
  • Thall PF; Department of Biostatistics, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Milton DR; Department of Biostatistics, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Fox PS; Department of Biostatistics, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Kawedia JD; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Kebriaei P; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Shah N; Department of Hematology and Blood and Marrow Transplant, University of California San Francisco, San Francisco, CA, USA.
  • Patel K; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Andersson BS; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Nieto YL; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Valdez BC; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Parmar S; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Rondon G; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Delgado R; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Hosing C; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Popat UR; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Oran B; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Ciurea SO; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Lin P; Department of Hematopathology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Weber DM; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Thomas SK; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Lee HC; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Manasanch EE; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Orlowski RZ; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Williams LA; Department of Symptom Research, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Champlin RE; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Qazilbash MH; Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
Lancet Haematol ; 6(5): e266-e275, 2019 May.
Article en En | MEDLINE | ID: mdl-30910541
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_cardiovascular_diseases / 6_lymphomas_multiple_myeloma Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_cardiovascular_diseases / 6_lymphomas_multiple_myeloma Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2019 Tipo del documento: Article